Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice
- 986 Downloads
Endometriosis is a debilitating disease with high recurrence rates requiring long-term management. Progestins such as dienogest are used empirically when first symptoms occur and post-surgery to reduce recurrence. This retrospective, practice-based study assessed the efficacy and safety of dienogest in women with endometriosis treated for at least 60 months.
37 women (age 39 ± 8 years) with laparoscopically diagnosed endometriosis received dienogest 2 mg orally once daily. Endometriosis-associated pelvic pain (EAPP) was measured on a 0–100 mm visual analog scale at baseline and every 12 months. Laboratory measures of lipid and liver metabolism, hemostatic and hormonal parameters were investigated in a subgroup of 15 women. Adverse events including bleeding disturbances and depressive symptoms were recorded.
In 22 women, dienogest was begun after laparoscopy; median EAPP score was 70 mm pre-surgery and 10, 10, 20, 20, and 20 mm, respectively, after 12, 24, 36, 48, and 60 months of dienogest treatment. Another 15 women began dienogest without prior surgery; median EAPP score was 80 mm pretreatment and 20, 20, 30, 30, and 30 mm, respectively, after 12, 24, 36, 48, and 60 months. All laboratory parameters remained within the normal range. Mean serum estradiol was 28 ± 12 pg/ml after 60 months. Seven women experienced spotting episodes and four women presented with phases of depressed mood, which could all be clinically managed.
Long-term (60-month) treatment with dienogest 2 mg once-daily in women with endometriosis effectively reduced EAPP and avoided pain recurrence post-surgery. Dienogest was well tolerated and adverse effects were clinically managed.
KeywordsDienogest Endometriosis Long-term management
Editorial assistance was provided by Bill Wolvey of PAREXEL International, which was contracted by Bayer AG.
TR participated in the project development, data collection and management, data analysis, and manuscript editing.
No study funding was received.
Compliance with ethical standards
Conflict of interest
Prof. Römer has received honoraria for lectures and advisory boards from: Bayer, MSD, Gedeon Richter, Dr. KADE, and Aristo Pharma.
Informed consent was obtained from all individual participants included in the study.
- 3.Soliman AM, Coyne KS, Zaiser E, Castelli-Haley J, Fuldeore MJ (2017) The burden of endometriosis symptoms on health-related quality of life in women in the United States: a cross-sectional study. J Psychosom Obstet Gynaecol 38(4):238–248. https://doi.org/10.1080/0167482X.2017.1289512 CrossRefPubMedGoogle Scholar
- 5.Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W, European Society of Human Reproduction and Embryology (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29(3):400–412. https://doi.org/10.1093/humrep/det457 CrossRefPubMedGoogle Scholar
- 14.Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N (2005) Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril 83(5):1530–1535. https://doi.org/10.1016/j.fertnstert.2004.11.042 CrossRefPubMedGoogle Scholar
- 16.Mita S, Shimizu Y, Notsu T, Imada K, Kyo S (2011) Dienogest inhibits Toll-like receptor 4 expression induced by costimulation of lipopolysaccharide and high-mobility group box 1 in endometrial epithelial cells. Fertil Steril 96(6):1485–1489 e1484. https://doi.org/10.1016/j.fertnstert.2011.09.040 CrossRefPubMedGoogle Scholar
- 17.Miyashita M, Koga K, Takamura M, Izumi G, Nagai M, Harada M, Hirata T, Hirota Y, Fujii T, Osuga Y (2014) Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 30(9):644–648. https://doi.org/10.3109/09513590.2014.911279 CrossRefPubMedGoogle Scholar
- 19.Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa N (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91(3):675–681. https://doi.org/10.1016/j.fertnstert.2007.12.080 CrossRefPubMedGoogle Scholar
- 21.Strowitzki T, Faustmann T, Gerlinger C, Seitz C (2010) Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 151(2):193–198. https://doi.org/10.1016/j.ejogrb.2010.04.002 CrossRefPubMedGoogle Scholar
- 22.Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C (2010) Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 25(3):633–641. https://doi.org/10.1093/humrep/dep469 CrossRefPubMedGoogle Scholar
- 25.Vercellini P, Bracco B, Mosconi P, Roberto A, Alberico D, Dhouha D, Somigliana E (2016) Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 105(3):734–743 e733. https://doi.org/10.1016/j.fertnstert.2015.11.016 CrossRefPubMedGoogle Scholar
- 30.Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA (2017) Dienogest and deep infiltrating endometriosis: the remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol 211:108–111. https://doi.org/10.1016/j.ejogrb.2017.02.015 CrossRefPubMedGoogle Scholar
- 35.Yamanaka A, Hada T, Matsumoto T, Kanno K, Shirane A, Yanai S, Nakajima S, Ebisawa K, Ota Y, Andou M (2017) Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstet Gynecol Reprod Biol 216:51–55. https://doi.org/10.1016/j.ejogrb.2017.07.014 CrossRefPubMedGoogle Scholar
- 36.Strowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C (2015) Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Womens Health 7:393–401. https://doi.org/10.2147/IJWH.S77202 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Revised American society for reproductive medicine classification of endometriosis: 1996 (1997). Fertil Steril 67(5):817–821Google Scholar
- 38.Visanne [prescribing information] (2016) Bayer AG: Leverkusen, Germany. Available at: http://www.bayerresources.com.au/resources/uploads/pi/file10142.pdf
- 39.Lang J, Zhang X, Zhou Y, Di W, Gude K, Dong L (2017) Efficacy and safety of dienogest in Chinese women with endometriosis: a 24-week, multicenter, randomized, placebo-controlled study with 28-week open-label phase. Presented at the 13th World Congress on Endometriosis, Vancouver, Canada, 17–20 May 2017Google Scholar
- 40.Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C (2010) Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes 8:138. https://doi.org/10.1186/1477-7525-8-138 CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Lee DY, Park HG, Yoon BK, Choi D (2016) Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis. Obstet Gynecol Sci 59(1):32–38. https://doi.org/10.5468/ogs.2016.59.1.32 CrossRefPubMedPubMedCentralGoogle Scholar